新冠疫苗接种后不良事件与抗SARS-CoV-2抗体浓度的关联:荷兰2021年5月至2022年11月人群前瞻性队列研究
该研究基于VASCO前瞻性队列,分析新冠疫苗接种后不良事件(AE)的决定因素及其与接种前后抗体浓度的关联。研究发现女性、年轻(<60岁)、有医学风险状况者及Spikevax接种者报告AE更频繁;接种前抗体浓度较高与第二、三剂后全身性AE发生率较高相关;第三剂后任何AE与接种后抗体浓度较高相关(几何平均浓度比1.38;95%CI:1.23-1.54)。
要点
- 女性、<60岁、有医学风险状况者及Spikevax接种者报告AE更频繁。
- 接种前抗体浓度较高与第二、三剂后全身性AE发生率较高相关。
- 第三剂后任何AE与接种后抗体浓度较高相关(几何平均浓度比1.38;95%CI:1.23-1.54)。
核心结论
- 研究提示接种前抗体水平较高与AE相关,且发生AE可能是对疫苗接种抗体反应较高的标志。
研究设计与样本
- 正在进行的 prospectieve cohort study(VASCO)的参与者完成接种后2个月内AE问卷,并在2021年5月至2022年11月期间提供6次每月血清样本。
- 共收到来自28,032名参与者的47,947份完整AE问卷。
- 采用逻辑回归分析mRNA疫苗接种后AE的决定因素,包括接种前针对SARS-CoV-2刺突蛋白受体结合域的Ig抗体浓度。
- 在SARS-CoV-2未感染参与者中采用多变量线性回归评估AE与mRNA疫苗接种后3-8周对数转化抗体浓度的关联。
主要发现
- 42%的问卷报告注射部位AE,34%报告全身性AE,2.2%的问卷中参与者寻求医疗关注。
- 女性、年轻参与者(<60岁)、有医学风险状况者及Spikevax接种者(vs Comirnaty)报告AE更频繁。
- 接种前抗体浓度较高与第二剂和第三剂后全身性AE发生率较高相关,但与注射部位AE或寻求医疗关注的AE无关。
- 第三剂后任何AE与接种后抗体浓度较高相关(几何平均浓度比:1.38;95%CI:1.23-1.54)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundNon-severe adverse events (AE) including pain at injection site or fever are common after COVID-19 vaccination.AimTo describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations.MethodsParticipants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within 2 months after vaccination and provided 6 monthly serum samples during May 2021-November 2022. Logistic regression analyses were performed to investigate AE determinants after mRNA vaccination, including pre-vaccination Ig antibody concentrations against the SARS-CoV-2 spike protein receptor binding domain. Multivariable linear regression was performed in SARS-CoV-2-naive participants to assess the association between AE and log-transformed antibody concentrations 3-8 weeks after mRNA vaccination.ResultsWe received 47,947 completed AE questionnaires by 28,032 participants. In 42% and 34% of questionnaires, injection site and systemic AE were reported, respectively. In 2.2% of questionnaires, participants sought medical attention. AE were reported more frequently by women, younger participants (< 60 years), participants with medical risk conditions and Spikevax recipients (vs Comirnaty). Higher pre-vaccination antibody concentrations were associated with higher incidence of systemic AE after the second and third dose, but not with injection site AE or AE for which medical attention was sought. Any AE after the third dose was associated with higher post-vaccination antibody concentrations (geometric mean concentration ratio: 1.38; 95% CI: 1.23-1.54).ConclusionsOur study suggests that high pre-vaccination antibody levels are associated with AE, and experiencing AE may be a marker for higher antibody response to vaccination.
引用
- Holwerda MR, Hoeve CE, Huiberts AJ, et al. Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study. Euro Surveill. 2024. PMID: 38904110. doi:10.2807/1560-7917.ES.2024.29.25.2300585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。